Seres Therapeutics (MCRB) EV to FCF (2015 - 2026)

Seres Therapeutics has disclosed EV to FCF across 12 years of filings, most recently posting 2.77 for Q2 2026.

• In Q2 2026, EV to FCF rose 28.3% year-over-year to 2.77; the TTM figure through Jun 2026 stood at 1.21 (down 40.53% YoY), while the FY2025 annual figure was 111.48, up 14802.12% from the prior year.
• EV to FCF came in at 2.77 for Q2 2026 at Seres Therapeutics, up from 3.38 in the prior quarter.
• In the past five years, EV to FCF ranged from a high of 55.05 in Q3 2025 to a low of 9.23 in Q4 2022.
• Average EV to FCF over 5 years is 0.3, with a median of 2.74 recorded in 2024.
• Year-over-year, EV to FCF plunged 758.47% in 2022 and soared 2134.44% in 2025.
• Over 5 years, EV to FCF stood at 9.23 in 2022, then jumped by 86.31% to 1.26 in 2023, then slumped by 129.55% to 2.9 in 2024, then tumbled by 125.7% to 6.54 in 2025, then surged by 57.72% to 2.77 in 2026.
• Per Business Quant data, the three most recent EV to FCF figures were 2.77 in Q2 2026, 3.38 in Q1 2026, and 6.54 in Q4 2025.